Biomarkers of Survival in Patients with Colorectal Liver Metastases Treated with Percutaneous Microwave Ablation
Simple Summary
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Cervantes, A.; Adam, R.; Roselló, S.; Arnold, D.; Le Kremlin-Bicêtre, M.; Kremlin-Bicêtre, L. Metastatic Colorectal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up 5 Behalf of the ESMO Guidelines Committee. Ann. Oncol. 2023, 34, 10–32. [Google Scholar] [CrossRef]
- Benson, A.B.; Venook, A.P.; Adam, M.; Chang, G.J.; Chen, Y.-J.; Ciombor, K.K.; Cohen, S.; Cooper, H.S.; Deming, D.; Garrido-Laguna, I.; et al. National Comprehensive Cancer Network 2025 Colon Cancer (Version 1.2025). Available online: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (accessed on 14 March 2025).
- Shady, W.; Petre, E.; Do, K.; Gonen, M.; Yarmohammadi, H.; Brown, K.; Kemeny, N.; Kingham, P.; Solomon, S.; Sofocleous, C. Percutaneous Microwave versus Radiofrequency Ablation of Colon Cancer Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control. J. Vasc. Interv. Radiol. 2018, 29, 268–275. [Google Scholar] [CrossRef]
- Odet, J.; Pellegrinelli, J.; Varbedian, O.; Truntzer, C.; Midulla, M.; Ghiringhelli, F.; Orry, D. Predictive Factors of Local Recurrence after Colorectal Cancer Liver Metastases Thermal Ablation. J. Imaging 2023, 9, 66. [Google Scholar] [CrossRef]
- Shady, W.; Petre, E.N.; Gonen, M.; Erinjeri, J.P.; Brown, K.T.; Covey, A.M.; Alago, W.; Durack, J.C.; Maybody, M.; Brody, L.A.; et al. Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes-a 10-Year Experience at a Single Center. Radiology 2016, 278, 601–611. [Google Scholar] [CrossRef]
- Han, K.; Kim, J.H.; Yang, S.G.; Park, S.H.; Choi, H.K.; Chun, S.Y.; Kim, P.N.; Park, J.; Lee, M. A Single-Center Retrospective Analysis of Periprocedural Variables Affecting Local Tumor Progression after Radiofrequency Ablation of Colorectal Cancer Liver Metastases. Radiology 2020, 298, 212–218. [Google Scholar] [CrossRef]
- Solbiati, L.; Livraghi, T.; Goldberg, S.N.; Ierace, T.; Meloni, F.; Dellanoce, M.; Cova, L.; Halpern, E.F.; Gazelle, G.S. Percutaneous Radio-Frequency Ablation of Hepatic Metastases from Colorectal Cancer: Long-Term Results in 117 Patients. Radiology 2001, 221, 159–166. [Google Scholar] [CrossRef]
- He, J.; Pan, H.; Liang, W.; Xiao, D.; Chen, X.; Guo, M.; He, J. Prognostic Effect of Albumin-to-Globulin Ratio in Patients with Solid Tumors: A Systematic Review and Meta-Analysis. J. Cancer 2017, 8, 4002–4010. [Google Scholar] [CrossRef]
- Templeton, A.J.; McNamara, M.G.; Šeruga, B.; Vera-Badillo, F.E.; Aneja, P.; Ocaña, A.; Leibowitz-Amit, R.; Sonpavde, G.; Knox, J.J.; Tran, B.; et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. J. Natl. Cancer Inst. 2014, 106, dju124. [Google Scholar]
- Deng, Y.; Zhang, F.; Yu, X.; Huo, C.L.; Sun, Z.G.; Wang, S. Prognostic Value Of Preoperative Systemic Inflammatory Biomarkers In Patients With Gallbladder Cancer And The Establishment Of A Nomogram. Cancer Manag. Res. 2019, 11, 9025–9035. [Google Scholar] [CrossRef]
- Lv, G.-Y.; An, L.; Sun, X.-D.; Hu, Y.-L.; Sun, D.-W. Pretreatment Albumin to Globulin Ratio Can Serve as a Prognostic Marker in Human Cancers: A Meta-Analysis. Clin. Chim. Acta 2018, 476, 81–91. [Google Scholar] [CrossRef]
- Ni, Z.H.; Wu, B.L.; Li, M.; Han, X.; Hao, X.W.; Zhang, Y.; Cheng, W.; Guo, C.L. Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation Based on Logistic Regression Analysis. Ultrasound Med. Biol. 2022, 48, 1733–1744. [Google Scholar] [CrossRef] [PubMed]
- Wang, S.; Deng, Y.; Yu, X.; Zhang, X.; Huo, C.; Sun, Z.; Chang, H. Prognostic Significance of Preoperative Systemic Inflammatory Biomarkers in Patients with Hepatocellular Carcinoma after Microwave Ablation and Establishment of a Nomogram. Sci. Rep. 2021, 11, 13814. [Google Scholar] [CrossRef]
- Luo, B.; Liu, L.; Bi, J.; Bao, S.; Zhang, Y. Role of the Pre- to Postoperative Alpha-Fetoprotein Ratio in the Prognostic Evaluation of Liver Cancer after Radiofrequency Ablation. Int. J. Biol. Markers 2022, 37, 306–313. [Google Scholar] [CrossRef]
- Facciorusso, A.; Del Prete, V.; Crucinio, N.; Serviddio, G.; Vendemiale, G.; Muscatiello, N. Lymphocyte-to-Monocyte Ratio Predicts Survival after Radiofrequency Ablation for Colorectal Liver Metastases. World J. Gastroenterol. 2016, 22, 4211–4218. [Google Scholar] [CrossRef]
- Huo, Y.R.; Glenn, D.; Liauw, W.; Power, M.; Zhao, J.; Morris, D.L. Evaluation of Carcinoembryonic Antigen (CEA) Density as a Prognostic Factor for Percutaneous Ablation of Pulmonary Colorectal Metastases. Eur. Radiol. 2017, 27, 128–137. [Google Scholar] [CrossRef] [PubMed]
- Peng, S.; Huang, P.; Yu, H.; Wen, Y.; Luo, Y.; Wang, X.; Zhou, J.; Qin, S.; Li, T.; Chen, Y.; et al. Prognostic Value of Carcinoembryonic Antigen Level in Patients with Colorectal Cancer Liver Metastasis Treated with Percutaneous Microwave Ablation under Ultrasound Guidance. Medicine 2018, 97. [Google Scholar] [CrossRef]
- van der Lei, S.; Puijk, R.S.; Dijkstra, M.; Schulz, H.H.; Vos, D.J.W.; De Vries, J.J.J.; Scheffer, H.J.; Lissenberg-Witte, B.I.; Aldrighetti, L.; Arntz, M.; et al. Thermal Ablation versus Surgical Resection of Small-Size Colorectal Liver Metastases (COLLISION): An International, Randomised, Controlled, Phase 3 Non-Inferiority Trial. Lancet Oncol. 2025, 26, 187–199. [Google Scholar] [CrossRef]
- Bergsland, E.; Bart Rose, J.; Benson, A.B.; Berman, Z.; Blaszkowsky, L.S.; Brock, P.; Chan, J.; Chatterjee, D.; Dickson, P.V.; Fingeret, A.; et al. National Comprehensive Cancer Network 2024 Neuroendocrine and Adrenal Tumors (Version 5.2024). Available online: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf (accessed on 14 March 2025).
- Glazer, E.S.; Tseng, J.F.; Al-Refaie, W.; Solorzano, C.C.; Liu, P.; Willborn, K.A.; Abdalla, E.K.; Vauthey, J.N.; Curley, S.A. Long-Term Survival after Surgical Management of Neuroendocrine Hepatic Metastases. HPB 2010, 12, 427. [Google Scholar] [CrossRef]
- Mohan, H.; Nicholson, P.; Winter, D.C.; O’Shea, D.; O’Toole, D.; Geoghegan, J.; Maguire, D.; Hoti, E.; Traynor, O.; Cantwell, C.P. Radiofrequency Ablation for Neuroendocrine Liver Metastases: A Systematic Review. J. Vasc. Interv. Radiol. 2015, 26, 935–942.e1. [Google Scholar] [CrossRef]
- Hua, Y.Q.; Wang, P.; Zhu, X.Y.; Shen, Y.H.; Wang, K.; Shi, W.D.; Lin, J.H.; Meng, Z.Q.; Chen, Z.; Chen, H. Radiofrequency Ablation for Hepatic Oligometastatic Pancreatic Cancer: An Analysis of Safety and Efficacy. Pancreatology 2017, 17, 967–973. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.T.; Yang, J.; Wu, J.; Lu, W.J. Combined Therapy of Chemotherapy and Radiofrequency Ablation for Pancreatic Cancer Patients With Metachronous Hepatic Metastatic Lesions After Radical Pancreatic Resection. Cancer Control 2024, 31, 10732748241274559. [Google Scholar] [CrossRef]
- Lee, S.J.; Kim, J.H.; Kim, S.Y.; Won, H.J.; Shin, Y.M.; Kim, P.N. Percutaneous Radiofrequency Ablation for Metachronous Hepatic Metastases after Curative Resection of Pancreatic Adenocarcinoma. Korean J. Radiol. 2020, 21, 316. [Google Scholar] [CrossRef] [PubMed]
- Clements, N.; Gaskins, J.; Martin, R.C.G. Surgical Outcomes in Stage IV Pancreatic Cancer with Liver Metastasis Current Evidence and Future Directions: A Systematic Review and Meta-Analysis of Surgical Resection. Cancers 2025, 17, 688. [Google Scholar] [CrossRef] [PubMed]
- Giuliante, F.; Panettieri, E.; Campisi, A.; Coppola, A.; Vellone, M.; De Rose, A.M.; Ardito, F. Treatment of Oligo-Metastatic Pancreatic Ductal Adenocarcinoma to the Liver: Is There a Role for Surgery? A Narrative Review. Int. J. Surg. 2024, 110, 6163. [Google Scholar] [CrossRef]
- Citterio, D.; Pusceddu, S.; Facciorusso, A.; Coppa, J.; Milione, M.; Buzzoni, R.; Bongini, M.; deBraud, F.; Mazzaferro, V. Primary Tumour Resection May Improve Survival in Functional Well-Differentiated Neuroendocrine Tumours Metastatic to the Liver. Eur. J. Surg. Oncol. 2017, 43, 380–387. [Google Scholar] [CrossRef]
- Chen, D.S.; Mellman, I. Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature 2017, 541, 321–330. [Google Scholar] [PubMed]
- Coussens, L.; Werb, Z. Inflammation and Cancer. Nature 2002, 420, 860–867. [Google Scholar]
- Mei, P.; Huang, L.; Lin, L.; Chen, Y.; Guo, X. The Prognostic Utility of the Ratio of Lymphocyte to Monocyte in Patients with Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Front. Oncol. 2025, 15, 1394154. [Google Scholar] [CrossRef]
- Han, Y.; Zheng, S.; Chen, Y.; Guo, Z.; Shiao, Y.-H. Prognostic Value of Lymphocyte to Monocyte Ratio in Patients with Esophageal Cancer: A Systematic Review and Meta-Analysis. Front. Oncol. 2024, 14, 1401076. [Google Scholar] [CrossRef]
- Hamid, H.K.S.; Emile, S.H.; Davis, G.N. Prognostic Significance of Lymphocyte-to-Monocyte and Platelet-to-Lymphocyte Ratio in Rectal Cancer: A Systematic Review, Meta-Analysis, and Meta-Regression. Dis. Colon Rectum 2022, 65, 178–187. [Google Scholar] [CrossRef]
- Steinberg-Vorhoff, H.L.; Tropotel, A.; Theysohn, J.M.; Schaarschmidt, B.; Haubold, J.; Jeschke, M.; Jochheim, L.; Ludwig, J.M. Evaluation of Inflammatory Markers as Prognostic Factors in the Treatment of Hepatocellular Carcinoma (HCC) with Degradable Starch Microspheres by Transarterial Chemoembolization (DSM-TACE). Cancers 2025, 17, 647. [Google Scholar] [CrossRef]
- Buisman, F.E.; Giardiello, D.; Kemeny, N.E.; Steyerberg, E.W.; Höppener, D.J.; Galjart, B.; Nierop, P.M.H.; Balachandran, V.P.; Cercek, A.; Drebin, J.A.; et al. Predicting 10-Year Survival after Resection of Colorectal Liver Metastases; an International Study Including Biomarkers and Perioperative Treatment. Eur. J. Cancer 2022, 168, 25–33. [Google Scholar] [CrossRef] [PubMed]
- Xie, H.; Wei, L.; Liu, M.; Liang, Y.; Wang, Q.; Tang, S.; Gan, J. Prognostic Value of Visceral Protein Ratios in Patients with Colon Cancer. Heliyon 2024, 10, e39326. [Google Scholar] [CrossRef]
- Zhang, Y.; Chen, M.; Peng, Z.; Chen, M.; Liu, F.; Huang, J.; Xu, L.; Zhang, Y. Elevated Neutrophil to Lymphocyte Ratio Might Predict Poor Prognosis for Colorectal Liver Metastasis after Percutaneous Radiofrequency Ablation. Int. J. Hyperth. 2012, 28, 132–140. [Google Scholar] [CrossRef]
- Chang, Z.; Zheng, J.; Ma, Y.; Zhao, J.; Wang, C.; Liu, Z. The Neutrophil-to-Lymphocyte Ratio as a Predictor for Recurrence of Colorectal Liver Metastases Following Radiofrequency Ablation. Med. Oncol. 2014, 31, 855. [Google Scholar] [CrossRef]
- Papakonstantinou, M.; Fiflis, S.; Christodoulidis, G.; Giglio, M.C.; Louri, E.; Mavromatidis, S.; Giakoustidis, D.; Papadopoulos, V.N.; Giakoustidis, A. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor for Survival in Patients with Colorectal Liver Metastases: A Systematic Review. World J. Clin. Oncol. 2022, 13, 822–834. [Google Scholar] [CrossRef]
- Zhou, F.; Yu, X.; Liang, P.; Han, Z.; Cheng, Z.; Yu, J.; Liu, F.; Hu, Y. Does Primary Tumor Location Impact the Prognosis of Colorectal Liver Metastases Patients after Microwave Ablation?—Lessons from 10 Years’ Experience. Oncotarget 2017, 8, 100791–100800. [Google Scholar] [CrossRef]
- Makowiec, F.; Menzel, M.; Bronsert, P.; Holzner, P.A.; Klock, A.; Lang, S.A.; Fichtner-Feigl, S.; Neeff, H.P. Does the Site of Primary Colorectal Cancer Influence the Outcome after Resection of Isolated Liver Metastases? Dig. Liver Dis. 2018, 50, 1088–1092. [Google Scholar] [CrossRef]
- Dijkstra, M.; Nieuwenhuizen, S.; Puijk, R.S.; Timmer, F.E.F.; Geboers, B.; Schouten, E.A.C.; Opperman, J.; Scheffer, H.J.; de Vries, J.J.J.; Versteeg, K.S.; et al. Primary Tumor Sidedness, RAS and BRAF Mutations and MSI Status as Prognostic Factors in Patients with Colorectal Liver Metastases Treated with Surgery and Thermal Ablation: Results from the Amsterdam Colorectal Liver Met Registry (AmCORE). Biomedicines 2021, 9, 962. [Google Scholar] [CrossRef] [PubMed]
- Creasy, J.M.; Sadot, E.; Koerkamp, B.G.; Chou, J.F.; Gonen, M.; Kemeny, N.E.; Saltz, L.B.; Balachandran, V.P.; Peter Kingham, T.; DeMatteo, R.P.; et al. The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer. Ann. Surg. Oncol. 2018, 25, 431–438. [Google Scholar] [CrossRef]
- Gu, Y.; Huang, Z.; Gu, H.; Fei, G.; Zhang, T.; Huang, S.; Huang, J. Does the Site of the Primary Affect Outcomes When Ablating Colorectal Liver Metastases with Radiofrequency Ablation? Cardiovasc. Interv. Radiol. 2018, 41, 912–919. [Google Scholar] [CrossRef]
- Fong, Y.; Fortner, J.; Sun, R.L.; Brennan, M.F.; Blumgart, L.H. Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer: Analysis of 1001 Consecutive Cases. Ann Surg 1999, 230, 309. [Google Scholar] [CrossRef] [PubMed]
Biomarker | Mean ± SD | Range | Cutoff Value |
---|---|---|---|
LMR | 3.44 ± 1.84 | 1.34–10.05 | 5.32 |
AGR | 1.66 ± 0.32 | 0.80–2.60 | 1.81 |
PLR | 131.09 ± 74.68 | 18.64–383.02 | 122.7 |
NLR | 2.36 ± 1.39 | 0.79–8.29 | 2.05 |
CEA [ng/mL] | 30.47 ± 59.97 | 0.32–323.00 | 29.1 |
CEA density [ng/mL·mm3] | 0.0019 ± 0.01 | 0.000004–0.07 | 0.00046 |
Variable | HR | HR (95% CI) | p-Value |
---|---|---|---|
LMR (reference > 5.32) | 4.05 | 1.62–10.12 | 0.003 * |
AGR (reference > 1.81) | 0.38 | 0.14–1.03 | 0.058 |
PLR (reference > 122.7) | 0.49 | 0.22–1.13 | 0.094 |
NLR (reference > 2.05) | 0.31 | 0.13–0.72 | 0.007 * |
CEA (reference > 29.1 ng/mL) | 3.70 | 1.68–8.14 | 0.001 * |
CEA density (reference > 0.00046 ng/mL·mm3) | 2.55 | 1.16–5.62 | 0.020 * |
Primary CRC location (reference left-sided) | 0.36 | 0.15–0.85 | 0.019 * |
Age | 1.00 | 0.97–1.03 | 0.924 |
Gender (reference male) | 1.34 | 0.60–2.96 | 0.472 |
Number of lesions | 1.04 | 0.74–1.46 | 0.837 |
Diameter (reference > 30 mm) | 1.07 | 0.46–2.50 | 0.875 |
Variable | HR | HR (95% CI) | p-Value |
---|---|---|---|
LMR (reference > 5.32) | 1.03 | 0.31–3.41 | 0.96 |
NLR (reference > 2.05) | 0.29 | 0.11–0.82 | 0.018 * |
CEA (reference > 29.1 ng/mL) | 4.10 | 1.60–10.54 | 0.003 * |
Primary CRC location (reference left-sided) | 0.25 | 0.10–0.64 | 0.004 * |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Franke, J.; Rosiak, G.; Milczarek, K.; Konecki, D.; Wnuk, E.; Cieszanowski, A. Biomarkers of Survival in Patients with Colorectal Liver Metastases Treated with Percutaneous Microwave Ablation. Cancers 2025, 17, 1112. https://doi.org/10.3390/cancers17071112
Franke J, Rosiak G, Milczarek K, Konecki D, Wnuk E, Cieszanowski A. Biomarkers of Survival in Patients with Colorectal Liver Metastases Treated with Percutaneous Microwave Ablation. Cancers. 2025; 17(7):1112. https://doi.org/10.3390/cancers17071112
Chicago/Turabian StyleFranke, Jakub, Grzegorz Rosiak, Krzysztof Milczarek, Dariusz Konecki, Emilia Wnuk, and Andrzej Cieszanowski. 2025. "Biomarkers of Survival in Patients with Colorectal Liver Metastases Treated with Percutaneous Microwave Ablation" Cancers 17, no. 7: 1112. https://doi.org/10.3390/cancers17071112
APA StyleFranke, J., Rosiak, G., Milczarek, K., Konecki, D., Wnuk, E., & Cieszanowski, A. (2025). Biomarkers of Survival in Patients with Colorectal Liver Metastases Treated with Percutaneous Microwave Ablation. Cancers, 17(7), 1112. https://doi.org/10.3390/cancers17071112